A Phase I-II, Multicenter, Open-Label Trial of Co-Administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Trial Profile

A Phase I-II, Multicenter, Open-Label Trial of Co-Administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2012

At a glance

  • Drugs Erlotinib; Tosedostat
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Apr 2008 as reported by ClinicalTrials.gov.
    • 31 Mar 2008 Status change from recruiting to discontinued, due to very poor recruitment. Information from clinicaltrials.gov.
    • 27 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top